

NB-006: Ramelteon Modified-Release



A a best-in-class modified-release formulation of ramelteon for insomnia characterized by difficulty with sleep onset and early awakening. This oral tablet targets the \$5B insomnia market with FDA and NMPA IND approval and robust patent protection.

NB-006: Best-in-Class Ramelteon Modified-Release

Addressing Insomnia Limitations

NB-006 is a best-in-class modified-release formulation of ramelteon for insomnia characterized by difficulty with sleep onset and early awakening. This oral tablet targets the **\$5B insomnia market** with **FDA and NMPA IND approval** and robust patent protection (CN: 202110950477.6; US18/288382).

The program has completed three pilot PK studies with results meeting expectations, and successfully manufactured a scale-up batch of 150,000 tablets, demonstrating manufacturing feasibility and commercial readiness.



Dual-Release Profile

Two pulse-like releases promote sleep onset and prevent early awakening, better meeting clinical needs than immediate-release formulations

Once-Daily Dosing

Single dose achieves effect of multiple administrations, improving compliance and patient convenience

Non-Controlled

Not a controlled substance, ensuring strong market accessibility and prescriber confidence

NB-006: Superior Profile Versus Takeda's Rozerem



Better Therapeutic Effect

The innovative dual pulse-like release profile of NB-006 addresses both sleep onset and maintenance, preventing early awakening that limits immediate-release ramelteon (Rozerem). This biphasic release more closely matches physiological sleep architecture and better fulfills clinical needs.



Enhanced Safety Profile

No drug dependence with minimal side effects distinguishes NB-006 from benzodiazepines and Z-drugs. The short half-life ensures minimal next-day hangover effects, addressing a major limitation of competing therapies and improving patient quality of life.



Improved Patient Compliance

Once-daily dosing achieves the therapeutic effect of multiple administrations, significantly reducing medication burden. This simplified regimen enhances adherence, particularly important in chronic insomnia management where compliance often determines treatment success.



Superior Pharmacokinetics

NB-006 demonstrates a **better PK profile than Takeda's Rozerem**, with optimized absorption kinetics, improved bioavailability, and controlled-release characteristics that sustain therapeutic levels throughout the night while clearing rapidly in the morning.

Market Advantage: As a non-controlled substance with demonstrated safety and efficacy advantages, NB-006 is positioned to capture significant market share from both prescription sleep aids and over-the-counter products.

Accelerating Innovation to Improve Patients' Lives

Navika Bio connects groundbreaking biotech innovation with global pharmaceutical partners to deliver transformative therapies to patients worldwide.



Let's Connect

For more information about partnership opportunities and to join us on this exciting journey of bringing transformative therapies to patients worldwide, please reach out to:



Lawrence Hu, PhD

**Chief Technology Officer
Head of Business Development**

Phone: 973-967-9949

Email: lawrence@navikabio.com

